COMPOSITIONS AND METHODS RELATED TO CANNABINOIDS, TERPENOIDS AND ESSENTIAL OILS

Abstract

The present invention provides cannabinoid and terpenoid compositions, among others, and methods of use including as medicines, supplements and nutraceuticals.

Claims

1. A composition, comprising: a combination of one or more synthetic cannabinoids and one or more synthetic terpenoids; wherein the composition substantially lacks a tetrahydrocannabinol.

2. The composition of claim 1, further including a pharmaceutically acceptable excipient.

3. The composition of claim 1, wherein the one or more terpenoids includes a myrcene compound.

4. The composition of claim 1, wherein the one or more cannabinoids are present in an amount of 5% or greater by weight and the one or more terpenoids are present in an amount of 5% or greater by weight.

5. The composition of claim 1, wherein the one or more cannabinoids are present in an amount of 10 mg or more and the one or more terpenoids are present in an amount of 10 mg or more.

6. A composition, comprising: one or more cannabinoid compounds and one or more essential oils of a plant, wherein the formulation substantially lacks a tetrahydrocannabinol (THC) and wherein the composition includes one of, or any combination of the essential oil of: howood, rosewood, coriander, linaloe, sweet basil linalool type, thyme linalool type and cardamom.

7. The composition of claim 6, including a myrcene compound.

8. The composition of claim 6, including a cannabidiol (CBD) compound.

9. The composition of claim 8, including a caryophyllene compound.

10. The composition of claim 6, including a cannabidiol compound and an essential oil of a ginseng plant, a sage plant or both.

11. The composition of claim 6, wherein the cannabinoid is one or more of a cannabidiol compound, a cannabinol compound and a cannabigerol compound.

12. A composition, comprising: one or more cannabinoids and at least one essential oil obtained from a valerian plant, a lavender plant or both, wherein the cannabinoid is one or more of a cannabidiol compound, a cannabinol compound, and a cannabigerol compound, or any combination thereof.

13. The composition of claim 12, wherein the one or more cannabinoids are synthetic cannabinoids.

14. The composition of claim 12, including one cannabinoid being the cannabinol compound and one essential oil being from the valerian plant or the lavender plant.

15. The composition of claim 12, including one cannabinoid being the cannabinol compound and one essential oil being from the valerian plant or the lavender plant.

16. The composition of claim 12, including one cannabinoid being the cannabigerol compound and one essential oil being from the valerian plant or the lavender plant.

17. A composition, comprising: one or more cannabinoids and a caryophyllene compound, wherein the cannabinoid is one or more of a cannabidiol compound, a cannabinol compound, and a cannabigerol compound, or any combination thereof.

18. The composition of claim 17, wherein the one or more cannabinoids are synthetic cannabinoids.

19. A method of alleviating a symptom of a pain, an inflammation or both in a subject in need thereof, comprising: administering an effective amount of a composition including a cannabinoid compound and a terpenoid compound, wherein the composition substantially lacks a tetrahydrocannabinol compound.

20. The method of claim 19, wherein the composition further includes a pharmaceutically acceptable excipient.

21. The method of claim 19, wherein the cannabinoid compound includes one or more of a cannabidiol compound, a cannabinol compound, and a cannabigerol compound or any combination thereof.

22. The method of claim 19, wherein the cannabinoid compound is the cannabinol compound, the cannabigerol compound or both.

23. The method of claim 19, having a synthetic cannabinoid compound.

24. The method of claim 19, having a synthetic terpenoid compound.

25. The method of claim 19, having a synthetic cannabinoid compound and a synthetic terpenoid compound.

26. The method of claim 19, including a caryophyllene compound, a myrcene compound or both.

Description

EXAMPLES

Example 1

[0037] Certain embodiments include myrcene, preferable -myrcene, which is a monoterpene and a common terpene produced by cannabis (some varieties contain up to 60% of the essential oil). Myrcene is found in the essential oil of hops, citrus fruits, bay leaves, eucalyptus, wild thyme, lemon grass and many other plants.

[0038] In certain embodiments, myrcene comprises one or more medicinal properties, including lowering the resistance across the blood to brain barrier, allowing itself and many other chemicals to cross the barrier more easily and/or more quickly. In certain embodiments, myrcene is included to enhance the effects of one or more cannabinoids, preferably enhancing a more rapid onset of cannabinoid effects. In certain embodiments, myrcene is included in a formulation of the present to increase the maximum saturation level of the CB1 receptor, allowing for a greater maximum psychoactive effect for THC.

[0039] In certain embodiments, myrcene is included in a formulation as a fragrance agent, preferably providing a scent of musky, earthy or herbal aromas.

[0040] Certain embodiments comprising a myrcene compound are useful as an analgesic, anti-inflammatory, antibiotic, antimutagenic or a combination thereof. Certain embodiments comprising a myrcene compound are useful for inhibition of cytochrome, aflatoxin B and other pro-mutagenic carcinogens. Certain embodiments comprising a myrcene compound are useful for treating gastric and duodenal ulcers or alleviating symptoms thereof in a subject or person in such need. Certain embodiments comprising a myrcene compound are useful for sedative and relaxing effects in a subject or person in need thereof. Certain embodiments comprising a myrcene compound are useful for treating insomnia or alleviating symptoms thereof in a subject or person in such need. Certain embodiments comprising a myrcene compound are useful for treating pain or alleviating symptoms of pain in a subject or person in such need. Certain embodiments comprising a myrcene compound are useful for treating inflammation or alleviating symptoms of inflammation in a subject or person in such need.

Example 2

[0041] Certain embodiments include linalool, which is a non-cyclic monoterpene. Certain embodiments comprising a linalool compound are useful for treating inflammation or alleviating symptoms of inflammation in a subject or person in such need. Certain embodiments comprising a linalool compound are useful for treating pain or alleviating symptoms of pain in a subject or person in such need. Certain embodiments comprising a linalool compound are useful for promoting calm and relaxation or for treating anxiety or for alleviating symptoms of anxiety in a subject or person in such need. Certain embodiments comprising a linalool compound are useful for promoting sleep or treating a sleep disturbance such as insomnia or alleviating symptoms of a sleep disturbance in a subject or person in such need. In certain embodiments, linalool is included in a formulation as a fragrance agent, preferably providing a scent of floral, especially lavender, aromas.

[0042] Linalool can be extracted from the Lamiaceae, Rutaceae, Lauraceae plant families, which include, for example: mints, laurels, cinnamon, rosewood and citrus plants. Linalool can also be extracted from birch and certain fungi.

Example 3

[0043] Certain embodied examples provide for pain relief in a subject or person in need of pain relief or for the alleviation of symptoms of pain using a formulation as follows.

Formula for Example 3

[0044] A formulation, comprising: one or more cannabinoids being CBD, CBN and/or CBG and one or more terpenoids including linalool. The formulation optionally further includes THC, but preferably lacks detectable levels of THC or has an insubstantial amount of THC (for example, a non-psychoactive amount). The formulation preferably includes at least one synthetic cannabinoid and/or at least one synthetic terpenoid.

Example

4

[0045] Certain embodied examples provide for pain relief in a subject or person in need of pain relief or for the alleviation of symptoms of pain using a formulation as follows.

Formula for Example

4

[0046] A formulation, comprising: one or more cannabinoids being CBD, CBN and/or CBG and one or more terpenoids including myrcene. The formulation optionally further includes THC, but preferably lacks detectable levels of THC or has an insubstantial amount of THC (for example, a non-psychoactive amount). The formulation preferably includes at least one synthetic cannabinoid and/or at least one synthetic terpenoid.

Example

5

[0047] Certain embodied examples provide for pain relief in a subject or person in need of pain relief or for the alleviation of symptoms of pain using a formulation as follows.

Formula for Example

5

[0048] A formulation, comprising: one or more cannabinoids being CBD, CBN and/or CBG and one or more terpenoids including caryophyllene (preferably caryophyllene oxide). The formulation optionally further includes THC, but preferably lacks detectable levels of THC or has an insubstantial amount of THC (for example, a non-psychoactive amount). The formulation preferably includes at least one synthetic cannabinoid and/or at least one synthetic terpenoid.

Example 6

[0049] Certain embodied examples provide for pain relief in a subject or person in need of pain relief or for the alleviation of symptoms of pain using a formulation as follows.

Formula for Example 6

[0050] A formulation, comprising: a CBD cannabinoid and one or more terpenoids, preferably a caryophyllene, a myrcene and/or a linalool. The formulation optionally further includes THC, but preferably lacks detectable levels of THC or has an insubstantial amount of THC (for example, a non-psychoactive amount). The formulation preferably includes at least one synthetic cannabinoid and/or at least one synthetic terpenoid.

Example 7

[0051] Certain embodied examples provide for pain relief in a subject or person in need of pain relief or for the alleviation of symptoms of pain using a formulation as follows.

Formula for Example 7

[0052] A formulation, comprising: a CBN cannabinoid and one or more terpenoids, preferably a caryophyllene, a myrcene and/or a linalool. The formulation optionally further includes THC, but preferably lacks detectable levels of THC or has an insubstantial amount of THC (for example, a non-psychoactive amount). The formulation preferably includes at least one synthetic cannabinoid and/or at least one synthetic terpenoid.

Example 8

[0053] Certain embodied examples provide for pain relief in a subject or person in need of pain relief or for the alleviation of symptoms of pain using a formulation as follows.

Formula for Example 8

[0054] A formulation, comprising: a CBG cannabinoid and one or more terpenoids, preferably a caryophyllene, a myrcene and/or a linalool. The formulation optionally further includes THC, but preferably lacks detectable levels of THC or has an insubstantial amount of THC (for example, a non-psychoactive amount). The formulation preferably includes at least one synthetic cannabinoid and/or at least one synthetic terpenoid.

Example 9

[0055] Certain embodied examples provide for pain relief in a subject or person in need of pain relief or for the alleviation of symptoms of pain using a formulation as follows.

Formula for Example 9

[0056] A formulation, comprising: a THC cannabinoid and one or more terpenoids, preferably a caryophyllene, a myrcene and/or a linalool. The formulation optionally further includes a CBD. The formulation preferably includes at least one synthetic cannabinoid and/or at least one synthetic terpenoid.

Example 10

[0057] Certain embodied examples provide for pain relief in a subject or person in need of pain relief or for the alleviation of symptoms of pain using a formulation as follows.

Formula for Example 10

[0058] A formulation, comprising: a THC cannabinoid and one or more terpenoids, preferably a caryophyllene, a myrcene and/or a linalool. The formulation optionally further includes a CBN cannabinoid, but preferably lacks detectable levels of a CBD cannabinoid or has an insubstantial amount of CBD cannabinoid present in the formulation. The formulation preferably includes at least one synthetic cannabinoid and/or at least one synthetic terpenoid.

Example 1

[0059] Certain embodied examples provide for pain relief in a subject or person in need of pain relief or for the alleviation of symptoms of pain using a formulation as follows.

Formula for Example 11

[0060] A formulation, comprising: a THC cannabinoid and one or more terpenoids, preferably a caryophyllene, a myrcene and/or a linalool. The formulation optionally further includes a CBG cannabinoid, but preferably lacks detectable levels of a CBD cannabinoid or has an insubstantial amount of CBD cannabinoid present in the formulation. The formulation preferably includes at least one synthetic cannabinoid and/or at least one synthetic terpenoid.

Example 12

[0061] A formulation of the present invention is administered by including carriers for vaping in the formulation (for example: propylene glycol, vegetable glycerin or both) and the subject (being a person in this example) inhales the formulation by vaping. Preferably, the subject inhales an amount sufficient to provide the subject with the desired effect (e.g., relaxation), treatment (e.g., reduced pain), therapy or alleviation of a symptom.

Example 13

[0062] A formulation of the present invention is combined with a transdermal permeation enhancer, a transdermal patch or a combination thereof and is applied to a skin of the subject. Preferably, an amount of the formulation is applied via the transdermal route sufficient to provide the subject with the desired effect (e.g., relaxation), treatment (e.g., reduced pain, reduced inflammation), therapy or alleviation of a symptom.

Example 14

[0063] A formulation of the present invention is provided in an intranasal spray, metered dose device or intranasal administration device and administered to the nasal cavity or by insufflation by the subject. Preferably, an amount of the formulation is applied via the intranasal route sufficient to provide the subject with the desired effect (e.g., relaxation), treatment (e.g., reduced pain, reduced inflammation), therapy or alleviation of a symptom.

Example 15

[0064] A formulation of the present invention is provided in a food or a dietary supplement for ingestion by a subject. Preferably, an amount of the formulation is provided in a serving of food or a serving of the dietary supplement to provide the subject with the desired effect (e.g., relaxation), treatment (e.g., reduced pain, reduced inflammation), therapy or alleviation of a symptom.

Example 16

[0065] A formulation of the present invention is provided as a nutraceutical or in a nutraceutical composition for use by a subject by a subject. Preferably, an amount of the formulation is provided in a dose or serving of the nutraceutical to provide the subject with the desired effect (e.g., relaxation), treatment (e.g., reduced pain, reduced inflammation), therapy or alleviation of a symptom.

[0066] Certain preferred embodiments of the present invention are not bound by a described mechanism of action.

[0067] Certain embodiments provide a product substantially as hereinbefore including as described in one or more embodiments or combination of embodiments and/or by reference to an example, figure, table or drawing.